On April 29, 2024, Gland Pharma Limited informed the stock exchanges that the company had received approval from the United States Food and Drug Administration (USFDA) for Cetrorelix Acetate for Injection, 0.25 mg/vial, Single-Dose Vial. The Cetrorelix Acetate for Injection, 0.25 mg/vial, Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), …